Search clinical trials for: Mirapex (pramipexole)

Total 156 results

Boehringer Ingelheim

Completed

In Vitro/in Vivo Correlation (IVIVC) for Oral Slow Release (SR) Tablets Pramipexole in Healthy Male Volunteers

Healthy
Massachusetts General Hospital

Recruiting

Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD

Sleep Disorder | Restless Legs Syndrome | Opioid-use Disorder | Opioid Withdrawal

United States
Boehringer Ingelheim

Completed

Bioavailability of Increasing Pramipexole Doses of Oral Extended Release (ER) Tablets in Healthy Male Volunteers

Healthy
Pharma Two B Ltd.

Completed

Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease

Parkinson's Disease

United States, Israel
Region Skane
Lund University

Recruiting

Pramipexole for Anhedonic Depression (PRIME-PRAXOL)

Depression | Anhedonia | Psychiatric Disorders Mood

Sweden
University of Oxford

Completed

Pramipexole and Emotional Processing (PEP)

Emotions | Motivation | Dopamine | Reward

United Kingdom
University of California, San Diego
National Institute of Mental Health (NIMH); New York State Psychiatric Institute

Recruiting

Pramipexole to Enhance Social Connections

Depression | Anxiety Disorders | Anxiety | Social Disconnection

United States
Seoul National University Hospital

Unknown

Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)

Parkinson's Disease

Korea, Republic of
Dong Jie

Terminated

Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis Patients

Restless Legs Syndrome

China
Baylor College of Medicine
National Institute on Drug Abuse (NIDA)

Completed

Pramipexole as a Treatment for Cocaine Dependence

Substance Abuse | Cocaine Dependence | Cocaine Abuse | Cocaine Addiction

United States
First Affiliated Hospital of Zhejiang University
Hongguan biological pharmaceutical co.

Terminated

Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets (PLKS-BE)

Parkinson's Disease

China
University of Pecs

Withdrawn

Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor

Essential Tremor

Hungary
Neuropsychiatric Research Institute, Fargo, North...

Withdrawn

Pramipexole for Binge Eating Disorder

Binge Eating Disorder
Boehringer Ingelheim

Completed

Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Terminated

Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome

Tourette Syndrome

United States, Germany
Dexa Medica Group

Completed

Bioequivalence Study of Two Formulations of Pramipexole Tablets 0.25 mg

Healthy

Indonesia
Boehringer Ingelheim

Completed

Increasing Dose Study of Pramipexole in Two-way Cross-over Comparison of ER Tablet Versus IR Tablet in Japanese Healthy Male Volunteers

Healthy
New York State Psychiatric Institute
National Institute of Mental Health (NIMH); Columbia University; Icahn School... and other collaborators

Completed

Imaging Dopamine Release in Depression

Major Depressive Disorder

United States
Region Skane
Lund University

Recruiting

Long-term Efficacy of Pramipexole in Anhedonic Depression (LONG-PRAXOL)

Depression | Anhedonia

Sweden
Boehringer Ingelheim

Completed

The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa

Parkinson Disease

China
Virginia Commonwealth University
Alzheimer's Drug Discovery Foundation; University of Kansas

Completed

Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease

Alzheimer's Disease

United States
Boehringer Ingelheim

Completed

Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease

Parkinson Disease

France, Germany, Netherlands
Rajesh Pahwa, MD
GlaxoSmithKline

Completed

Pramipexole Conversion to Ropinirole Controlled Release (CR)

Parkinson Disease

United States
Massachusetts General Hospital
National Institute of Mental Health (NIMH)

Completed

Effectiveness of Pramipexole for Treatment-Resistant Depression

Depression

United States
University of New Mexico
University of New Mexico Clinical and Translational Science Center

Completed

Non-Opioid Pramipexole and Pain

Chronic Pain

United States
Boehringer Ingelheim

Completed

Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients

Parkinson Disease

China
East Carolina University

Unknown

Pramipexole and Morphine for Renal Colic

Renal Colic

United States
Dr. D McIntosh & Dr. K Kjernisted Clinical Research...
AstraZeneca

Completed

Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride

Bipolar Depression

United States, Canada
Augusta University
GlaxoSmithKline

Completed

SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole

Restless Legs Syndrome

United States
Teva Pharmaceuticals USA

Completed

Pramipexole Dihydrochloride 0.25 mg Tablets Under Fasting Conditions

Healthy

United States
Boehringer Ingelheim

Completed

Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male Volunteers

Healthy

China
Teva Pharmaceuticals USA

Completed

Pramipexole Dihydrochloride 0.25 mg Tablets Under Non-Fasting Conditions

Healthy

United States
Boehringer Ingelheim

Completed

A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period

Parkinson Disease

Japan
Boehringer Ingelheim

Completed

A Randomised, Comparing Fixed Doses of Pramipexole to Investigate the Efficacy and Safety in Patients With RLS.

Idiopathic Restless Legs Syndrome

Japan
Boehringer Ingelheim

Terminated

Pramipexole ER vs. Placebo in Fibromyalgia

Fibromyalgia

United States
Boehringer Ingelheim

Completed

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

Parkinson Disease

United States, Austria, Finland, France, Germany, Italy, Japan, Spain, Sweden, United Kingdom
Northwell Health
Stanley Medical Research Institute

Completed

Cognitive Enhancement in Bipolar Disorder

Bipolar Disorder

United States
Boehringer Ingelheim

Completed

Long-term Administration Study of SND 919 Tablets in Parkinson's Disease

Parkinson Disease
Boehringer Ingelheim

Completed

Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome

Restless Legs Syndrome

Japan
Brigham and Women's Hospital
National Institute of Mental Health (NIMH); Northwell Health; Icahn School of... and other collaborators

Completed

Targeting Cognition in Bipolar Disorder With Pramipexole (PRAM-BD)

Bipolar Disorder

United States
Bennett, James P., Jr., M.D., Ph.D.
University of Pittsburgh

Completed

R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States
Boehringer Ingelheim

Completed

Safety and Effect of Mirapex(Pramipexole) Tablet Among Korean RLS

Restless Legs Syndrome

Korea, Republic of
Region Skane
Lund University

Completed

Pramipexole to Target "Anhedonic Depression" (PILOT-PRAXOL)

Anhedonia | Depression, Unipolar | Dysthymia | Depression, Bipolar

Sweden
National Institute of Mental Health (NIMH)

Completed

Clinical Trial of Pramipexole in Bipolar Depression

Bipolar Disorder

United States
National Institute of Mental Health (NIMH)

Completed

Lexapro and Pramipexole and to Treat Major Depression

Major Depression

United States
Sandoz

Completed

Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease

Parkinson's Disease

Korea, Republic of
Boehringer Ingelheim

Completed

Study to Investigate Pharmacokinetics (PK) of Pramipexole in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)

Restless Legs Syndrome
University Health Network, Toronto

Terminated

Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease

Parkinson's Disease | Peripheral Edema

Canada
Boehringer Ingelheim

Completed

Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances

Depression | Restless Legs Syndrome

Finland, France, Germany, Ireland, Italy, Korea, Republic of, Spain, Sweden, United Kingdom
Abbott Products

Terminated

A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.

Advanced Stage Parkinson's Disease

Germany, Italy, Portugal

Search clinical trials for: Mirapex (pramipexole)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations